New hope for bile duct cancer: immunotherapy plus chemo after surgery
NCT ID NCT05430698
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing whether adding an immunotherapy drug (PD-1 antibody) to standard chemotherapy (GEMOX) after surgery can help prevent cancer from returning in people with perihilar cholangiocarcinoma that has spread to nearby lymph nodes. The study plans to enroll 62 adults aged 18-75 who have had their tumor removed with clear margins but still have cancer in their lymph nodes. Participants will receive up to 8 cycles of the drug combination, and researchers will track how many remain cancer-free after 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PD-1 antibody plus gemcitabine and oxaliplatin (GEMOX) chemotherapy
- What this could lead to
- If successful, this combination could improve the chance of staying cancer-free for at least a year after surgery for people with this rare bile duct cancer.
- What could go wrong
- This is a small, early-phase trial with no comparison group, so results may not be definitive. The treatment combines chemotherapy and immunotherapy, which can cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIHILAR CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 376032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heat therapy before stenting may extend bile duct patency in cancer patients
- String-Attached stent may ease bile duct cancer surgery prep
- Personalized cancer care: new trial aims to improve outcomes in biliary cancer
- New stent technique may lower infection risk in bile duct cancer patients
- Liver transplant offers new hope for incurable bile duct cancer
- Promising combo therapy shows hope for Hard-to-Treat bile duct cancer